AstraZeneca plc (ADR)  

(Public, NYSE:AZN)   Watch this stock  
Find more results for AZN
73.91
+0.25 (0.34%)
Nov 26 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range 73.65 - 74.15
52 week 55.23 - 82.68
Open 73.76
Vol / Avg. 626,715.00/1.92M
Mkt cap 92.43B
P/E 90.96
Div/yield 0.90/3.79
EPS 0.81
Shares 1.26B
Beta 0.55
Inst. own 7%
Feb 5, 2015
Full Year 2014 AstraZeneca PLC Earnings Release Add to calendar
Nov 18, 2014
AstraZeneca PLC Investor Day - Webcast
Nov 6, 2014
Q3 2014 AstraZeneca PLC Earnings Call - Webcast
Nov 6, 2014
Q3 2014 AstraZeneca PLC Earnings Release
Sep 28, 2014
AstraZeneca PLC European Society for Medical Oncology (ESMO) 2014 Analysts and Investors Briefing
Sep 23, 2014
AstraZeneca PLC at EBD Group BioPharm America
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin 3.87% 10.00%
Operating margin 8.27% 14.44%
EBITD margin - 31.92%
Return on average assets 1.77% 4.70%
Return on average equity 4.80% 10.89%
Employees 51,500 -
CDP Score - 85 B

Address

2 Kingdom Street, Paddington
LONDON, ENG W2 6BD
United Kingdom - Map
+44-20-76048000 (Phone)
+44-20-76048151 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

AstraZeneca PLC (AstraZeneca) is a global biopharmaceutical company. AstraZeneca discovers, develops and commercializes prescription medicines for six areas of healthcare: Cardiovascular, Gastrointestinal, Infection, Neuroscience, Oncology, and Respiratory and Inflammation. It has a range of medicines that includes treatments for illnesses, such as its antibiotic, Merrem/Meronem and Losec/Prilosec for acid related diseases. AstraZeneca�s products include Crestor, Atacand,Seloken/Toprol-XL, Plendil, Onglyza, Zestril, Symbicort and Zoladex. The Company owns and operates a range of research and development (R&D), production and marketing facilities worldwide. AstraZeneca operates in over 100 countries, including China, Mexico, Brazil and Russia. In January 2014, Probiodrug AG transferred its experimental cyclin-dependent kinase 9 (CDK9) inhibitor program to AstraZeneca. In February 2014, Bristol-Myers Squibb Co completed the sale of its global diabetes business to AstraZeneca.

Officers and directors

Pascal Soriot Chief Executive Officer, Executive Director
Age: 55
Bio & Compensation  - Reuters
Marc Dunoyer Chief Financial Officer, Executive Director
Age: 61
Bio & Compensation  - Reuters
Ruud Dobber Executive Vice President, Europe
Bio & Compensation  - Reuters
Caroline Hempstead Interim Executive Vice-President, Human Resources & Corporate Affairs
Bio & Compensation  - Reuters
Paul Hudson Executive Vice President, North America
Bio & Compensation  - Reuters
Bahija Jallal Ph.D. Executive Vice President, MedImmune
Bio & Compensation  - Reuters
Mark Mallon Executive Vice President, International
Bio & Compensation  - Reuters
Briggs Morrison Executive Vice President - Global Medicines Development
Bio & Compensation  - Reuters
Menelas Pangalos Executive Vice President - Innovative Medicines
Bio & Compensation  - Reuters
David Smith Executive Vice President - Operations and Information Services
Bio & Compensation  - Reuters